Home » PTO Grants Reissued Patent Replacing OSI Pharma’s Tarceva Patent
PTO Grants Reissued Patent Replacing OSI Pharma’s Tarceva Patent
OSI Pharmaceuticals, Inc. Tuesday announced that the U.S. Patent & Trademark
Office has granted reissue patent RE41,065, replacing Tarceva’s (erlotinib) composition of matter patent.
StreetInsider
StreetInsider
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May